Identification of four snoRNAs (SNORD16, SNORA73B, SCARNA4, and SNORD49B) as novel non-invasive biomarkers for diagnosis of breast cancer

Table 2 Correlation between plasma snoRNAs expression and clinicopathologic characteristics of early-stage BC patients

Characteristics		SNORD16		SNORA73B		SCARNA4		SNORD49B
Characteristics		Case No.	P value	Case No.	P value	Case No.	P value	Case No.	P value
Age	≤ 51	65	0.6872	66	0.6830	65	0.7079	66	0.2119
Age	> 51	61	0.6872	61	0.6830	60	0.7079	59	0.2119
T stage	Tis	8	0.0258*	8	0.1096	8	0.1389	7	0.0038*
	T1	53		55		55		54
	T2	60		59		57		59
	T3	5		5		5		5
Lymph node metastasis	N0	88	0.4689	88	0.2685	86	0.4420	87	0.3159
Lymph node metastasis	N1	38	0.4689	39	0.2685	39	0.4420	38	0.3159
TNM stage	Tis	8	0.0180*	8	0.0376*	8	0.1020	7	0.0052*
	I	42		43		43		43
	II	76		76		74		75
ER	-	41	0.2434	40	0.4287	39	0.1063	39	0.0357*
ER	+	85	0.2434	87	0.4287	86	0.1063	86	0.0357*
PR	-	54	0.6593	53	0.8912	51	0.1058	52	0.0646
PR	+	72	0.6593	74	0.8912	74	0.1058	73	0.0646
HER2	-	89	0.4923	89	0.2675	88	0.3720	88	0.4828
	+	32		32		31		32
	Unknown	5		6		6		5
Ki67	-	32	0.1004	32	0.1578	30	0.5481	31	0.6476
Ki67	+	94	0.1004	95	0.1578	95	0.5481	94	0.6476
Subtype	Luminal	74	0.1595	74	0.1641	73	0.1344	74	0.2740
	HER2-enriched	28		28		27		28
	Triple-negative	15		15		15		14
	Unknown	9		10		10		9

ISSN: 1475-2867